Assessing the role of volumetric brain information in multiple sclerosis progression.

Journal: Computational and structural biotechnology journal
Published Date:

Abstract

Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system. Understanding multiple sclerosis progression and identifying the implicated brain structures is crucial for personalized treatment decisions. Deformation-based morphometry utilizes anatomical magnetic resonance imaging to quantitatively assess volumetric brain changes at the voxel level, providing insight into how each brain region contributes to clinical progression with regards to neurodegeneration. Utilizing such voxel-level data from a relapsing multiple sclerosis clinical trial, we extend a model-agnostic feature importance metric to identify a robust and predictive feature set that corresponds to clinical progression. These features correspond to brain regions that are clinically meaningful in MS disease research, demonstrating their scientific relevance. When used to predict progression using classical survival models and 3D convolutional neural networks, the identified regions led to the best-performing models, demonstrating their prognostic strength. We also find that these features generalize well to other definitions of clinical progression and can compensate for the omission of highly prognostic clinical features, underscoring the predictive power and clinical relevance of deformation-based morphometry as a regional identification tool.

Authors

  • Andy A Shen
    Department of Statistics, UC Berkeley, Berkeley, CA, USA.
  • Aidan McLoughlin
    Division of Biostatistics, UC Berkeley, Berkeley, CA, USA.
  • Zoe Vernon
    Department of Statistics, UC Berkeley, Berkeley, CA, USA.
  • Jonathan Lin
    Department of Statistical Science, Duke University, Durham, NC, USA.
  • Richard A D Carano
    From the Department of Product Development-Personalized HealthCare Imaging (A.P.K., Z.S., T.B., R.A.D.C.), Clinical Imaging Group, gRED (D.C., A.d.C.), and DevSci OMNI-Biomarker Development (X.J.), Genentech, 600 E Grand Ave, South San Francisco, CA 94080; and Global Product Development Medical Affairs, Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland (L.G.).
  • Peter J Bickel
    Department of Statistics, UC Berkeley, Berkeley, CA, USA.
  • Zhuang Song
    From the Department of Product Development-Personalized HealthCare Imaging (A.P.K., Z.S., T.B., R.A.D.C.), Clinical Imaging Group, gRED (D.C., A.d.C.), and DevSci OMNI-Biomarker Development (X.J.), Genentech, 600 E Grand Ave, South San Francisco, CA 94080; and Global Product Development Medical Affairs, Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland (L.G.).
  • Haiyan Huang
    Department of Crop and Soil Sciences, Washington State University, Pullman, WA 99164, USA.

Keywords

No keywords available for this article.